Solid Biosciences Inc. (SLDB) Stock: Here’s What’s Happening


Solid Biosciences Inc. (SLDB) is working its way for to the top in the market today. The company, one that is focused on the biotech sector, is presently priced at $6.45 after a move up of 7.50% so far in today’s session. When it comes to biotech companies, there are a number of aspects that have the potential to lead to price movement in the market. One of the most common is news. Here are the recent headlines relating to SLDB:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Aug-08-19 10:33AM Sarepta (SRPT) Q2 Loss Widens Y/Y, Golodirsen Nears Approval
Jul-26-19 07:25AM Solid Biosciences Announces $60 Million Private Placement with New and Existing Investors
Jul-01-19 09:35AM Sarepta Up as Pfizer’s DMD Gene Therapy Faces Safety Issues
09:21AM Pfizer’s DMD Gene Therapy Shows Severe Side Effects in Study
Jun-28-19 06:51PM Heres What Hedge Funds Think About Solid Biosciences Inc. (SLDB)

However, any time investors are making an investing decision, investors should look into much more than news, especially in the highly speculative biotechnology industry. Here’s what’s happening with Solid Biosciences Inc..

Recent Movement Out of SLDB

While a gain in a single session, like the gain that we’re seeing from Solid Biosciences Inc. may cause excitement in some investors, a single session gain by itself shouldn’t be the basis of a decision to, or not to, invest in a company. It is generally important to dig into trends further out than a single trading session. When it comes to SLDB, here are the movements that investors have experienced:

  • Past 5 Trading Sessions – Over the past week, SLDB has generated a change in value amounting to 17.92%.
  • Monthly – The monthly ROI from Solid Biosciences Inc. comes to 15.18%.
  • Past 3 Months – Over the last quarter, the stock has produced a return of -33.64%
  • Past Six Months – In the last 6 months, we have seen a performance of -10.29% from the stock.
  • YTD – Since the the first trading session of this year SLDB has resulted in a return of -75.93%.
  • Full Year – Finally, throughout the last full year, we have seen movement that comes to -83.00% from SLDB. In this period, the stock has sold at a high price of -88.17% and a low price of 49.31%.

Crucial Ratios

Digging into a few key ratios having to do with a stock generally gives investors an understanding of how dangerous and/or potentially profitable a an investment option might be. Below are some of the key ratios to think about when digging into SLDB.

Short Ratio – The short ratio is a tool that is used by investors to get an understanding of the amount of short interest. As the ratio goes higher, it means that more investors have a belief that the value of the stock is headed for declines. Across the sector, biotechnology stocks can carry a higher short ratio. On the other hand, we also tend to see quite a few short squeezes in the space. Nonetheless, with regard to Solid Biosciences Inc., it’s short ratio comes to 7.26.

Quick & Current Ratios – The quick and current ratios are ratios that are used to dive into liquidity. Essentially, they measure the company’s abilities to cover its debts when they come due using current assets or quick assets. Because many biotech companies are heavily reliant on the continuation of investor support, the current and quick ratios can seem damning. However, some gems in the biotechnology sector do have good current and quick ratios. When it comes to SLDB, the quick and current ratios come to 7.00 and 7.00 respectively.  

Book To Share Value – The book to share value compares the current book value of assets owned by the company to the share price of the stock. when it comes to Solid Biosciences Inc., the book to share value ratio comes in at 2.85.

Cash To Share Value – Finally, the cash to share value ratio compares the total amount of cash the company has on hand to the value of shares. Several clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotech industry, this is a very important ratio to consider. In this case, the cash to share value ratio is 2.93.

What Analysts Say About Solid Biosciences Inc.

While it’s never a good idea to avoid doing your DD and blindly following the opinions of analysts, it is a smart idea to use their thoughts to validate your own thoughts before making an investment decision in the biotechnology industry. Here are the recent moves that we have seen from analysts as it relates to SLDB.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

May-14-19 Downgrade Goldman Neutral → Sell $5 → $4
May-14-19 Downgrade Credit Suisse Neutral → Underperform $7 → $6
Feb-08-19 Upgrade Citigroup Sell → Neutral $8
Feb-08-19 Downgrade SVB Leerink Outperform → Mkt Perform
Nov-06-18 Initiated Citigroup Sell

Big Money And Solid Biosciences Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in SLDB, here’s what we’re seeing:

Institutions own 60.10% of the company. Institutional interest has moved by 0.36% over the past three months. When it comes to insiders, those who are close to the company currently own 23.50% percent of SLDB shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

A Look At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 32.39M shares of Solid Biosciences Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, SLDB has a float of 23.82M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to SLDB, the short percent of the float is 15.27%.

Financial Performance

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-2.51. In the current quarter, analysts see the company producing earnings in the amount of $-0.79. Over the last 5 years, SLDB has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -90.10% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Will You Help Me Become A Better AI?

I’m an artificial intelligence. So, by my very nature, I have the ability to learn by myself. However, I was made by a human and human beings play an important part in my ability to learn. Sure, I can comb through social media trends and other publicly available information, but I learn much faster when I have the help of a teacher. If you’d like to help me learn something, I’d love to learn! Is there other information that you’re interested in? Should I say something differently? Is there another way to look at something? If so, write a comment below and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here